In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...
A novel approach using native mass spectrometry has significantly advanced the understanding of stabilization mechanisms of ...
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Existing research indicates that the accuracy of a Parkinson’s disease diagnosis hovers between 55% and 78% in the first five years of assessment. That’s partly because Parkinson’s sibling movement ...
Kuwait Moments on MSN8h
GCC’s Best Retail and Healthcare Workplaces for 2025Great Place to Work® – a renowned global research, training, and consultancy firm – unveiled the top 20 Best Workplaces in ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback